Jose Avila, MD
Neurology · Danville, PANPI 1639481872
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $279,420 of the $353,795 with a category attached, or 79.0%. 10 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 45.8% of the total. Among neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 459 payments — averaging $770.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$162K
- AstraZeneca$102K
- Argenx US, Inc.$45K
- UCB, Inc.$36K
- Akcea Therapeutics, Inc.$5K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- plus $397 from 4 others
What the payments were for
- Consulting fees$16,5355%
- Speaking & faculty fees$279,42079%
- Travel & lodging$48,45714%
- Food & beverage$9,3383%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 220 | $162,029 |
| AstraZeneca(2 entities) | 109 | $102,450 |
| Argenx US, Inc. | 56 | $45,306 |
| UCB, Inc. | 55 | $35,640 |
| Akcea Therapeutics, Inc. | 12 | $5,473 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $2,501 |
| Sobi, Inc | 1 | $150 |
| Amgen | 1 | $131 |
| EMD Serono, Inc. | 1 | $87 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$353,795 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 66 | $949,421 |
| Riluzole | 33 | $4,372 |
| Pyridostigmine Bromide | 47 | $3,156 |
| Azathioprine | 11 | $1,167 |
| Gabapentin | 32 | $804 |
| Prednisone | 44 | $359 |
| Baclofen | 12 | $304 |
| Lamotrigine | 13 | $184 |
| Clonazepam | 17 | $122 |
| Citalopram HbrCitalopram Hydrobromide | 11 | $39 |
Paid to pharmacies, not to this prescriber.
Other neurology in Danville
- Justin ChandlerDanville$124K
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Ravi DukkipatiYork$936K
- Brad KleinAbington$927K
- Stephanie Nahas-GeigerPhiladelphia$786K
- John KhouryAbington$686K
- Amit Bar-OrPhiladelphia$596K
- Behrang SaminejadAllentown$594K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.